ASTELLAS PHARMA UNSP.ADR (YPHA F) stock market data APIs
€11.687
0(0%)
as of January 22, 2026
Try our APIs with
free plan!
ASTELLAS PHARMA UNSP.ADR Financial Data Overview
Price chart is built with
Anychart
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Prev. Close
11.687
Open
11.687
High
11.687
Low
11.687
52 wk Range
7.3252-12.5
Market Cap
21 767 M
P/E Ratio
31.8919
Shares Outstanding
1 791 M
Revenue
2 006 816 M
Dividends (Yield)
0.0378
Beta
0.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTELLAS PHARMA UNSP.ADR data using free add-ons & libraries
Get ASTELLAS PHARMA UNSP.ADR Fundamental Data
ASTELLAS PHARMA UNSP.ADR Fundamental data includes:
- Net Revenue: 2 006 816 M
- EBITDA: 563 083 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTELLAS PHARMA UNSP.ADR News
New
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) shares rallied 5.9% in the last trading session to close at $15.8. This move can be attributable to notable volume with a higher number of shares being traded than in a ty...
Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump?
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether Astellas Pharma's current share price still offers value, this...
Ocular Launches, And Then Slides, On Rumors Sanofi Is Preparing A Bigger Bid
Shares of Ocular Therapeutix launched and then retreated Thursday on reports Sanofi is preparing an improved bid to buy it. Continue Reading
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with VYLOY ...
Get ASTELLAS PHARMA UNSP.ADR fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
